Antiangiogenic Agents in Cancer Therapy

Por Ledermann, Jonathan A
Publicado em 1999

PARP inhibitors in ovarian cancer: Clinical evidence for informed treatment decisions

Por Ledermann, Jonathan A, El-Khouly, Fatima
Publicado no Br J Cancer (2015)

Treatment options in recurrent ovarian cancer: latest evidence and clinical potential

Por Luvero, Daniela, Milani, Andrea, Ledermann, Jonathan A.
Publicado em 2014

Pre-clinical assessment of autologous DC-based therapy in ovarian cancer patients with progressive disease

Por Hardwick, Nicola, Ledermann, Jonathan A., Aitkens, Egla, Chain, Benny
Publicado em 2012

Olaparib treatment for BRCA-mutant ovarian cancer with leptomeningeal disease

Por Bangham, Madeleine, Goldstein, Robert, Walton, Henry, Ledermann, Jonathan A
Publicado no Gynecol Oncol Rep (2016)

Setting up non-commercial clinical trials takes too long in the UK: findings from a prospective study

Por Hackshaw, Allan, Farrant, Hannah, Bulley, Sue, Seckl, Michael J, Ledermann, Jonathan A
Publicado em 2008

Prolonged response of relapsed high grade serous ovarian carcinoma to the oral angiokinase inhibitor nintedanib in a patient with a germline BRCA1 mutation

Por Wong, Han Hsi, Parkinson, Christine, Ledermann, Jonathan A., Brenton, James D., Merger, Michael, Shaw, Ashley, Patterson, Aileen, Shafi, Mahmood, Earl, Helena M.
Publicado em 2012

Inhibition of carboplatin-induced DNA interstrand crosslink repair by gemcitabine in patients receiving these drugs for ‘platinum-resistant’ ovarian cancer

Por Ledermann, Jonathan A, Gabra, Hani, Jayson, Gordon C, Spanswick, Victoria J, Rustin, Gordon JS, Jitlal, Mark, James, Lindsay E, Hartley, John A
Publicado no Clin Cancer Res (2010)

Evidence for different mechanisms of ‘unhooking’ for melphalan and cisplatin-induced DNA interstrand cross-links <it>in vitro</it> and in clinical acquired resistant tumour samples...

Por Spanswick Victoria J, Lowe Helen L, Newton Claire, Bingham John P, Bagnobianchi Alessia, Kiakos Konstantinos, Craddock Charles, Ledermann Jonathan A, Hochhauser Daniel, Hartley John A
Publicado em 2012-09-01

Evidence for different mechanisms of ‘unhooking’ for melphalan and cisplatin-induced DNA interstrand cross-links in vitro and in clinical acquired resistant tumour samples

Por Spanswick, Victoria J, Lowe, Helen L, Newton, Claire, Bingham, John P, Bagnobianchi, Alessia, Kiakos, Konstantinos, Craddock, Charles, Ledermann, Jonathan A, Hochhauser, Daniel, Hartley, John A
Publicado em 2012

Better Therapeutic Trials in Ovarian Cancer

Por Bookman, Michael A., Gilks, C. Blake, Kohn, Elise C., Kaplan, Karen O., Huntsman, David, Aghajanian, Carol, Birrer, Michael J., Ledermann, Jonathan A., Oza, Amit M., Swenerton, Kenneth D.
Publicado em 2014

Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer

Por Ledermann, Jonathan A, Harter, Philipp, Gourley, Charlie, Friedlander, Michael, Vergote, Ignace, Rustin, Gordon, Scott, Clare, Meier, Werner, Shapira-Frommer, Ronnie, Safra, Tamar, Matei, Daniela, Fielding, Anitra, Bennett, Bryan, Parry, David, Spencer, Stuart, Mann, Helen, Matulonis, Ursula
Publicado no Br J Cancer (2016)

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial

Por Oza, Amit M, Cook, Adrian D, Pfisterer, Jacobus, Embleton, Andrew, Ledermann, Jonathan A, Pujade-Lauraine, Eric, Kristensen, Gunnar, Carey, Mark S, Beale, Philip, Cervantes, Andrés, Park-Simon, Tjoung-Won, Rustin, Gordon, Joly, Florence, Mirza, Mansoor R, Plante, Marie, Quinn, Michael, Poveda, Andrés, Jayson, Gordon C, Stark, Dan, Swart, Ann Marie, Farrelly, Laura, Kaplan, Richard, Parmar, Mahesh K B, Perren, Timothy J
Publicado no Lancet Oncol (2015)